Waters Corporation

WAT Healthcare Diagnostics & Research

Waters Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 6.99% from fiscal 2024. In the quarter to June 2026, revenue grew 113.4%, EPS fell 156.3%, free cash flow grew 750.0% and total debt rose 308.2%, each against the same quarter a year earlier. Member of the S&P 500; insiders bought in the last twelve months.

436.95 7.20 −1.62%
Market cap
$43.6B
P/E
109×
Fwd P/E
44.3×
Dividend yield
—
F-score
5/9
Altman Z
9.63
Beneish M
−2.37
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

32.96% 29.27% 5.21% 1.92%
Piotroski F-Score
6 5 2 4
ROA
13.83% 13.35% 3.09% 1.13%
ROIC
18.28% 17.17% 1.92% 1.05%
Return on Tangible Assets
49.69% 41.43% 13.58% 4.69%
Average Days of Receivables
87.97 95.59 169.71 156.16
Free Cash Flow per Share
10.12 8.53 2.82 3.73
Free Cash Flow
602.27 507.60 231.60 366.60
Other line items

Show all line items

Columns are period end dates